Cathie Wood’s ARK Invest has been aggressively purchasing Nvidia, Broadcom, and Intellia Therapeutics on recent market dips, reinforcing the firm’s conviction in artificial intelligence infrastructure and gene-editing therapeutics as transformative investment themes heading into the final quarter of 2026.
ARK bought approximately 243,707 shares of Nvidia worth roughly $55.6 million following the chipmaker’s strong fiscal Q2 earnings report in late August, according to trading data. The purchases came as investors rotated within the semiconductor sector, with ARK simultaneously trimming its AMD holdings while deepening its Nvidia position across multiple exchange-traded funds.
Broadcom shares also attracted fresh buying from ARK during the same period. The semiconductor company’s stock declined after the firm’s revenue forecast disappointed investors compared with Nvidia’s more robust guidance, creating what Wood’s team viewed as a buying opportunity in a critical AI infrastructure provider.
In the biotech arena, ARK has been building its stake in Intellia Therapeutics, a gene-editing company focused on in vivo CRISPR-based therapies. Intellia shares traded near $12.67 as of early September, down sharply from the stock’s 52-week high of $28.25, giving ARK an entry point aligned with the firm’s broader pivot toward early-stage biotechnology firms throughout 2026.
This buying activity reflects ARK’s established investment pattern. Wood’s firm has repeatedly deployed capital during market pullbacks, purchasing SpaceX shares during a 23% price decline in June and adding to semiconductor positions during multiple August sell-offs. ARK Invest’s total portfolio reached approximately $15.4 billion in Q2 2026, with holdings spanning 191 companies focused on disruptive innovation.
ARK’s strategy centers on two core conviction themes. On the AI infrastructure side, the firm has emphasized that global AI spending could triple to $1.4 trillion by 2030, positioning chipmakers like Nvidia and Broadcom as essential beneficiaries. Simultaneously, ARK has shifted focus toward early-stage biotech, betting that gene editing and genomics will reshape healthcare. The firm’s Genomic Revolution ETF specifically targets DNA sequencing, CRISPR technology, and molecular diagnostics.
The timing of these purchases underscores Wood’s contrarian approach. While many investors fled semiconductor and biotech stocks on disappointing guidance and valuation concerns, ARK viewed the declines as opportunities to add to positions in companies it believes will drive long-term returns. Intellia’s consensus price target of $21.15, representing 66.5% upside from early September levels, reflects analyst confidence in the gene-editing space despite near-term volatility.
Whether Wood’s bets on AI infrastructure and gene editing will pay off remains uncertain. However, her willingness to buy during periods of weakness—when others are selling—has been a defining characteristic of her investment approach throughout 2026, even as her flagship ARK Innovation ETF navigates broader market swings.
Sources
- Yahoo Finance — Cathie Wood’s recent purchases of Nvidia, Broadcom, and SpaceX across multiple dates in August and early September 2026
- Investing.com — ARK’s daily trading records for Intellia Therapeutics and other biotech stocks in late August and early September 2026
- Seeking Alpha — ARK Invest’s Q2 2026 13F portfolio update showing $15.4 billion in assets and 191 holdings
- MacroTrends and MarketWatch — Intellia Therapeutics historical stock prices and 52-week ranges as of early September 2026
- ARK Invest — Company strategy pages detailing the Genomic Revolution ETF and disruptive innovation framework
- Reuters and LinkedIn — Broadcom’s September 2, 2026 earnings forecast disappointment relative to Nvidia
- FinViz and Benzinga — ARK’s semiconductor purchases in August 2026 during chip sector volatility
